文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

早期连续性肾脏替代治疗在重症肺炎集束化治疗中的应用

[Application of early continuous renal replacement therapy in the bundle treatment of severe pneumonia].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2018-01-01
一句话结论重症肺炎集束化治疗中早期加用CVVH可降低7天ARDS发生率(11.43% vs 31.43%)和病死率(0% vs 11.43%),并更早降低PCT、TNF-α、IL-6及升高CD4+。

该研究纳入2013年1月至2017年6月徐州医科大学第二附属医院呼吸重症监护病房(RICU)收治的70例重症肺炎患者,随机分为常规治疗组和CRRT治疗组各35例,均接受集束化治疗,CRRT组在此基础上每日行CVVH(每次持续8-24小时)。结果显示,CRRT组第3天PCT和TNF-α较常规组显著降低,CD4+显著升高,IL-6自第5天起显著降低;CRRT组7天内ARDS发生率(11.43% vs 31.43%)和病死率(0% vs 11.43%)均显著低于常规组。作者认为,在重症肺炎集束化治疗早期行CRRT不仅有助于清除炎症介质、改善免疫功能,而且是减少并发症、延缓病情快速进展的有效途径。

要点

  • 重症肺炎集束化治疗中早期加用CVVH(每日1次,每次8-24小时)可降低7天ARDS发生率:CRRT组11.43%(4/35)vs 常规组31.43%(11/35),P<0.05。
  • CRRT组7天病死率为0%(0/35),常规组为11.43%(4/35),两组差异有统计学意义(P<0.05)。
  • CRRT组第3天PCT(μg/L)3.11±1.28 vs 常规组3.76±1.42、TNF-α(ng/L)98.61±11.58 vs 119.47±12.38,均显著降低(P<0.05)。
  • CRRT组CD4+在第3天显著高于常规组(0.39±0.03 vs 0.35±0.03,P<0.05);IL-6的下降延迟,自第5天起显著低于常规组(ng/L)35.43±12.39 vs 52.86±10.78。
  • 作者认为,重症肺炎集束化治疗早期行CRRT是减少并发症、延缓病情快速进展的有效途径,为综合治疗提供机会和条件。

适用人群与场景

  • 2013年1月至2017年6月徐州医科大学第二附属医院呼吸重症监护病房(RICU)收治的重症肺炎患者70例,随机分为常规治疗组和CRRT治疗组各35例。

处置流程与药物剂量

  • 两组均接受集束化治疗;CRRT治疗组在常规集束化治疗基础上每日行CRRT,模式为连续性静脉-静脉血液滤过(CVVH),每次持续8-24小时。

研究设计与关键结果

  • 随机对照研究,纳入70例重症肺炎患者(每组35例),比较常规集束化治疗与加用每日CVVH的疗效。
  • 治疗前两组血清PCT、IL-6、TNF-α及CD4+无显著差异;随治疗时间延长,PCT、IL-6、TNF-α逐渐下降,CD4+逐渐升高。
  • CRRT组第3天PCT(μg/L)3.11±1.28 vs 常规组3.76±1.42、TNF-α(ng/L)98.61±11.58 vs 119.47±12.38,均显著降低(P<0.05);CD4+显著升高(0.39±0.03 vs 0.35±0.03,P<0.05)。
  • CRRT组IL-6下降延迟,第5天起显著低于常规组(ng/L)35.43±12.39 vs 52.86±10.78(P<0.05)。
  • CRRT组7天内ARDS发生率11.43%(4/35)vs 常规组31.43%(11/35),病死率0%(0/35)vs 11.43%(4/35),均显著降低(P<0.05)。

证据类型、等级与局限

  • 研究类型:随机对照研究;证据等级及推荐强度原文未报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在重症肺炎集束化治疗早期行CRRT不仅有助于清除炎症介质、改善免疫功能,而且是减少并发症、延缓病情快速进展的有效途径,为综合治疗提供机会和条件。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the role of early continuous renal replacement therapy (CRRT) in bundle treatment of severe pneumonia.

METHODS: Seventy severe pneumonia patients admitted to respiratory intensive care unit (RICU) of Second Affiliated Hospital of Xuzhou Medical University from January 2013 to June 2017 were enrolled. The patients were randomly divided into routine treatment group and CRRT treatment group, with 35 patients in each group. All patients were treated with bundle therapy, and those in CRRT treatment group was treated with CRRT daily on the basis of conventional bundle therapy. The mode was continuous veno-venous hemofiltration (CVVH), lasting 8-24 hours at a time. On the day of admission and the treatment of 1, 3, 5, 7 days, the fasting venous blood was collected. Inflammatory stress and immune parameters including procalcitonin (PCT), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and CD4+ cells were determined by enzyme linked immunosorbent assay (ELISA) or flow cytometer. The incidence of acute respiratory distress syndrome (ARDS) and mortality within 7 days were observed in the two groups.

RESULTS: Seventy patients with severe pneumonia were enrolled. There was no significant difference in the serum PCT, IL-6, TNF-α or CD4+ before treatment between the two groups. With the prolongation of treatment time, the PCT, IL-6 and TNF-α levels were gradually decreased, and the CD4+ was gradually increased. Compared with routine treatment group, PCT and TNF-α in CRRT treatment group were significantly decreased since the 3rd day [PCT (μg/L): 3.11±1.28 vs. 3.76±1.42, TNF-α (ng/L): 98.61±11.58 vs. 119.47±12.38], and CD4+ was significantly increased (0.39±0.03 vs. 0.35±0.03, all P < 0.05). The changes in IL-6 of CRRT treatment group was delayed, the statistical significance was found since the 5th day as compared with routine treatment group (ng/L: 35.43±12.39 vs. 52.86±10.78, P < 0.05). Compared with routine treatment group, the incidence of ARDS [11.43% (4/35) vs. 31.43% (11/35)] and mortality [0% (0/35) vs. 11.43% (4/35)] within 7 days in CRRT treatment group were significantly lowered (both P < 0.05).

CONCLUSIONS: CRRT in the early stage of bundle therapy for severe pneumonia is not only suggested to remove inflammatory mediators and improve immune function, but an opportunity and effective way to reduce complications and delay rapid progression of severe pneumonia. It provides the opportunity and condition for comprehensive treatment.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Xu J, Zhao J, Jia X, et al. [Application of early continuous renal replacement therapy in the bundle treatment of severe pneumonia]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29519284. doi:10.3760/cma.j.issn.2095-4352.2018.03.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。